RFK Jr. Announces Major Actions to Lower Drug Prices for Americans

Addressing High Drug Costs

• 💡 Millions of Americans struggle to afford essential medicines, with families rationing prescriptions and seniors skipping doses.
• 📌 The traditional pharmaceutical system, established by the 1984 Hatch-Waxman Act, worked for chemistry-based drugs but failed for biologics.
• ⚠️ Biologic drugs, made from living cells, constitute only 5% of prescriptions but account for over half of all drug spending, with some costing up to $500,000 annually.

Regulatory Barriers and Monopolies

• 📈 Pharmaceutical industry lobbying between 2007-2009 rigged rules, making biosimilar approval difficult and expensive, creating a market that lags significantly behind Europe.
• 🚫 Government bureaucracy and outdated FDA processes have protected monopolies, stifled competition, and slowed the entry of lower-cost biosimilars.
• 💰 The high cost of biologics is ultimately borne by American workers through health insurance deductions and Medicare excise taxes.

FDA's New Actions for Competition

• ✅ The FDA is issuing new draft guidance for biosimilar development, allowing companies to bypass large human trials if advanced testing proves efficacy and safety.
• ⏱️ This reform is expected to cut biosimilar development time in half (from 5-8 years to 2.5-5 years) and save companies over $100 million in development costs.
• 🔄 New guidance will also promote interchangeability, enabling pharmacists to substitute biosimilars for brand-name biologics, similar to traditional generics.

Impact and Future Outlook

• 📊 Since 2015, biosimilars have already saved Americans over $56 billion, costing 50% less than brand-name counterparts and driving down original drug prices by 25%.
• 🎯 These reforms aim to restore competition, empower patients, and significantly lower drug costs, aligning with President Trump's directive.
• 📣 CMS is also working to improve reimbursement models and increase transparency in the market, including publishing drug prices via "Trump RX" to offer more options.